Adopted opinions and previous consultations on applications for authorisation

Adopted opinions and previous consultations on applications for authorisation

Adopted opinions and previous consultations on applications for authorisation

This page provides further information on the applications for authorisation or review reports, which have undergone consultation. The applications for authorisation are in the opinion development phase until the final opinions of the Committees for Risk Assessment and Socio-economic Analysis have been adopted and sent to the European Commission. Its decision-making process can be followed through the comitology register, where further information is published about the REACH Committee's past and upcoming meetings.

On 1 February 2020, the United Kingdom (UK) withdrew from the EU. The transition period provided by the withdrawal agreement ended on 31 December 2020. As of 1 January 2021, an application for an authorisation submitted by a person established in the UK (except Northern Ireland) is no longer valid in the EU, unless that application has been transferred to a legal entity established in the EU or Northern Ireland before the end of the transition period. Therefore, authorisation applications and decisions in so far as these concern persons established in the UK (except Northern Ireland) are no longer considered valid. 

 

There are currently no ongoing consultations.
 
0234-02 Initial Chromium trioxide 215-607-8 1333-82-0 Maschinenfabrik Kaspar Walter GmbH & Co KG Chromium trioxide-based functional chrome plating of cylinders used in the rotogravure printing and embossing industry. Commission decided Details
0235-01 Initial Chromic acid 231-801-5 7738-94-5 Neoperl GmbH The use of chromic acid in the functional electroplating of brass-made sanitary articles with the specific purpose of obtaining a final Cr(0) coating that provides a surface with high durability and chemical resistance. Commission decided Details
0236-01 Initial Sodium dichromate 234-190-3
7789-12-0
10588-01-9
Robur S.p.A Use of sodium dichromate as an anticorrosion agent of the carbon steel in sealed circuit of gas absorption appliances up to 1.05% w/w (corresponding to 0.42% w/w as Cr VI) in the refrigerant solution Opinions adopted Details
0237-01 Initial Chromium trioxide 215-607-8 1333-82-0 Carlo Nobili SPA Rubinetterie Use at industrial site electroplating of different types of substrates to achieve functional surfaces with high durability and a bright or matt silvery appearance for sanitary applications Opinions adopted Details
0238-01 initial Chromium trioxide 215-607-8 1333-82-0 Hueck-Engraving GmbH & Co.KG Functional chrome plating of high-quality stainless-steel press plates for the premium wood-based materials industry Commission decided Details
0239-01 initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Prionics Lelystad B.V Use as component of buffer solutions to produce antigens (Cell extraction, cell lysis, coating of biological antigens onto articles, inactivation of microorganisms that produce targeted antigen and solvent exchange) and in-process and final Quality Control of antigens intended for use as veterinary and human health laboratory reagents in Scientific Research and Development and In Vitro Diagnostic applications Commission decided Details
0239-02 Initial 4-Nonylphenol, branched and linear, ethoxylated - - Prionics Lelystad B.V. Use as component of buffer solutions to produce antigens (Cell extraction, cell lysis, coating of biological antigens onto articles, inactivation of microorganisms that produce targeted antigen and solvent exchange) and in-process and final Quality Control of antigens intended for use as veterinary and human health laboratory reagents in Scientific Research and Development and In Vitro Diagnostic applications Commission decided Details
0240-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Alexion Pharma International Operations Unlimited Company Industrial use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated for virus inactivation in the manufacture Andexanet alfa for treatment of adult patients treated with a direct factor Xa (FXa) inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding Commission decided Details
0241-01 Initial Chromium trioxide 215-607-8 1333-82-0 Gessi S.p.A.
San Marco Rubinetteria S.r.l.
Use of chromium trioxide for electroplating of metal substrates with the purpose of creating a long-lasting high durability surface with bright look for kitchen and bathroom sanitaryware (functional plating with decorative character) Opinions adopted Details
0242-01 Review report Trichloroethylene 201-167-4 79-01-6 Microporous GmbH Trichloroethylene used as extraction solvent in the manufacture of polyethylene separators for lead-acid batteries Commission decided Details